Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion Biotech (NASDAQ: EVAX) will present its Q1 2021 financial results on May 13, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Dial-in numbers: US: 877-407-0792, International: +1-201-689-8263, Conference ID: 13718732. An audio webcast will be available on Evaxion's website. The company develops AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline including three patient-specific cancer treatments currently in Phase 1/2a trials.
Evaxion Biotech (Nasdaq: EVAX) announced a significant presentation by Dr. Jens Kringelum at the 4th Neoantigen Summit Europe, focusing on AI's role in personalized cancer medicine. The discussion highlighted advancements in predicting cancer neoepitopes using peptide-MHC complex stability. Evaxion's AI platform, PIONEER, is continuously evolving, leveraging new methods for enhanced immunotherapy design. CEO Lars Wegner emphasized the efficiency gains in drug development from these improvements. The company is developing a range of patient-specific immunotherapies and vaccines to address bacterial and viral infections.
Evaxion Biotech A/S (Nasdaq: EVAX) reported strong progress in its Q4 and full year 2020 results, highlighted by a successful IPO in February 2021 that raised $30 million. The company has cash reserves of $5.8 million as of Dec 31, 2020, which have been bolstered by IPO proceeds, ensuring funding into 2022. Clinical trials for their cancer vaccine EVX-02 are on track, with anticipated data releases in Q2 2021. However, the company reported a net loss of $15 million for 2020 with increased R&D and administrative expenses compared to the previous year.
Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology firm, will announce its 2020 financial results on April 6, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Evaxion specializes in AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline that includes three patient-specific cancer immunotherapies in development and a preclinical vaccine program against S. aureus, including MRSA. Interested parties can access dial-in and webcast details through provided links.
Evaxion Biotech A/S (NASDAQ: EVAX) announced a publication in Scientific Reports, detailing a collaborative study with the University of Southern Denmark on S. aureus infections. The study utilized dual RNA sequencing to explore host-pathogen interactions, revealing insights into the bacterium's virulence factors. CEO Lars Wegner highlighted the importance of these findings for developing targeted vaccines via Evaxion's EDEN AI platform. The company is advancing a portfolio of immunotherapies and vaccines, including a program against S. aureus infections.
Evaxion Biotech (Nasdaq: EVAX) has opened a new corporate headquarters and research facility in the DTU Science Park, Hoersholm, Denmark. This facility consolidates its diverse operations from Denmark and Italy under one roof, designed to foster collaboration among bioinformaticians and clinical teams. The 60-employee-capacity site will support ongoing research and future expansions. CEO Lars Wegner highlighted that this move aims to enhance the development of AI-driven immunotherapies targeting cancer and infectious diseases, with current projects in various clinical stages.
Evaxion Biotech has successfully completed its initial public offering (IPO), issuing 3,000,000 American Depositary Shares (ADSs) at a public offering price of $10.00 per ADS, raising $30 million in gross proceeds. The shares commenced trading on the Nasdaq Capital Market under the symbol 'EVAX' on February 5, 2021. The underwriters have an option to purchase an additional 450,000 ADSs within 30 days. Evaxion focuses on developing AI-driven immunotherapies targeting cancer and infectious diseases, currently advancing several clinical programs including patient-specific cancer immunotherapies.